Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia

Leukemia and Lymphoma

Volumn 49, Issue 6, 2008, Pages 1104-1107

  Leleu, Xavier ^a,b   Moreau, Anne Sophie ^a,b   Weller, Edie ^c   Roccaro, Aldo M ^a   Coiteux, ValeRie ^b   Manning, Robert ^a   Nelson, Marybeth ^a   Leduc, Renee ^a   Robu, Daniela ^b   Dupire, Sophie ^b   Hatjiharissi, Evdoxia ^a   Burwick, Nicholas ^a   Darre, Stephane ^b   Hennache, Bernadette ^b   Treon, Steven P ^a   Facon, Thierry ^b   Gertz, Morie A ^d   Ghobrial, Irene M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Mayo Clinic   (United States)

Author keywords

Serum free light chain; Tumor burden marker; Waldenstrom macroglobulinemia

Indexed keywords

ALKYLATING AGENT; FLUDARABINE; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; RITUXIMAB; TUMOR MARKER;

ACCURACY; ADULT; AGED; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; IMMUNOGLOBULIN M; INTERNATIONAL AGENCIES; MALE; MIDDLE AGED; PARAPROTEINEMIAS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; WALDENSTROM MACROGLOBULINEMIA;

EID: 46749092617     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802074619     Document Type: Article

References (15)

1. Treon, S. P., Gertz, M. A., Dimopoulos, M., Anagnostopoulos, A., Blade, J. Branagan, A. R. et al. (2006) Update on treatment recommendations from the third international workshop on Waldenstrom's macroglobulinemia. Blood, 107, pp. 3442-3446.
2. Morel, P., Duhamel, A., Gobbi, P., Dimopoulos, M., Dhodapkar, M. McCoy, J. et al. (2006) International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia (WM). Blood, 108, p. 42a.
3. Dhodapkar, M. V., Jacobson, J. L., Gertz, M. A., Rivkin, S. E., Roodman, G. D. Tuscano, J. M. et al. (2001) Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood, 98, pp. 41-48.
4. Mead, G. P., Carr-Smith, H. D., Drayson, M. T., Morgan, G. J., Child, J. A. and Bradwell, A. R. (2004) Serum free light chains for monitoring multiple myeloma. Br J Haematol, 126, pp. 348-354.
5. Mayo, M. M. and Johns, G. S. (2007) Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias. Contrib Nephrol, 153, pp. 44-65.
6. Durie, B. G., Harousseau, J. L., Miguel, J. S., Blade, J., Barlogie, B. Anderson, K. et al. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, p. 2220.
7. Rajkumar, S. V., Kyle, R. A., Therneau, T. M., Clark, R. J., Bradwell, A. R. Melton III, L. J. et al. (2004) Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol, 127, pp. 308-310.
8. Gertz, M. A., Lacy, M. Q., Dispenzieri, A. and Hayman, S. R. (2005) Amyloidosis: Diagnosis and management. Clin Lymphoma Myeloma, 6, pp. 208-219.
9. Owen, R. G., Treon, S. P., Al-Katib, A., Fonseca, R., Greipp, P. R. McMaster, M. L. et al. (2003) Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol, 30, pp. 110-115.
10. Katzmann, J. A., Abraham, R. S., Dispenzieri, A., Lust, J. A. and Kyle, R. A. (2005) Diagnostic performance of quantitative κ and λ free light chain assays in clinical practice. Clin Chem, 51, pp. 878-881.
11. Dispenzieri, A., Lacy, M. Q., Katzmann, J. A., Rajkumar, S. V., Abraham, R. S. Hayman, S. R. et al. (2006) Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 107, pp. 3378-3383.
12. Drayson, M., Tang, L. X., Drew, R., Mead, G. P., Carr-Smith, H. and Bradwell, A. R. (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood, 97, pp. 2900-2902.
13. Nowrousian, M. R., Brandhorst, D., Sammet, C., Kellert, M., Daniels, R. Schuett, P. et al. (2005) Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res, 11, pp. 8706-8714.
14. Dimopoulos, M. A., Kyle, R. A., Anagnostopoulos, A. and Treon, S. P. (2005) Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol, 23, pp. 1564-1577.
15. Ghobrial, I. M., Fonseca, R., Gertz, M. A., Plevak, M. F., Larson, D. R. Therneau, T. M. et al. (2006) Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol, 133, pp. 158-164.